The utility of muscarinic agonists in the treatment of alzheimer’s disease-Reference-Cited by-同舟云学术

The utility of muscarinic agonists in the treatment of alzheimer’s disease

Published:2002-08 Issue:1-2 Volume:19 Page:187-193
ISSN:0895-8696
Container-title:Journal of Molecular Neuroscience
language:en
Short-container-title:J Mol Neurosci

Author:

Messer William S.

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12031-002-0031-5.pdf

Reference40 articles.

1. Bartus R. T., Dean R. L. D., Beer B., and Lippa A. S. (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217(4558), 408–414.

2. Bodick N. C., Offen W. W., Levey A. I., Cutler N. R., Gauthier S. G., et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54(4), 465–473.

3. Brann M. R., Buckley N. J., Jones S. V., and Bonner T. I. (1987) Expression of a cloned muscarinic receptor in A9 L cells. Mol. Pharmacol. 32(4), 450–455.

4. Buxbaum J. D., Ruefli A. A., Parker C. A., Cypess A. M., and Greengard P. (1994) Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc. Natl. Acad. Sci. USA 91(10), 4489–4493.

5. Bymaster F. P., Carter P. A., Peters S. C., Zhang W., Ward J. S., Mitch C. H., et al. (1998) Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res. 795(1–2), 179–190.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Potential Application of [¹¹C]MK‐6884;Contemporary Accounts in Drug Discovery and Development;2022-03-07

2. Drug development and Alzheimer's disease;Pathy's Principles and Practice of Geriatric Medicine;2022-02-18

3. Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders;Biomedicines;2022-02-07

4. Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial;Journal of Psychiatric Research;2021-12

5. Electron Donor–Acceptor Properties of Different Muscarinic Ligands: On the Road to Control Schizophrenia;Journal of Chemical Information and Modeling;2021-09-24